Plasma fibrinogen, tissue plasminogen activator, plasminogen activator inhibitor 1, and their related factors in three Japanese population samples
暂无分享,去创建一个
H. Iso | K. Koike | M. Iida | Y. Komachi | U. Umemura | M. Kudo | Y. Naito | T. Shimamoto | S. Sato
[1] M. Taskinen,et al. The insulin resistance syndrome and postprandial lipid intolerance in smokers. , 1997, Atherosclerosis.
[2] P C Elwood,et al. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. , 1996, European heart journal.
[3] C. Jern,et al. Enhanced levels of tissue-type plasminogen activator in borderline hypertension. , 1995, Hypertension.
[4] M. Taskinen,et al. The insulin resistance syndrome in smokers is related to smoking habits. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[5] G. Mancia,et al. Mechanisms Responsible for Sympathetic Activation by Cigarette Smoking in Humans , 1994, Circulation.
[6] J. Seidell,et al. Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. , 1994, Atherosclerosis.
[7] A. Folsom,et al. Antigens of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor 1: Correlates in Nonsmoking Japanese and Caucasian Men and Women , 1993, Thrombosis and Haemostasis.
[8] A. Folsom,et al. Plasma fibrinogen and its correlates in Japanese and US population samples. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[9] P. Ridker,et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction , 1993, The Lancet.
[10] G. Reaven,et al. Insulin resistance and cigarette smoking , 1992, The Lancet.
[11] T. Urano,et al. PAI-1 Plays an Important Role in the Expression of t-PA Activity in the Euglobulin Clot Lysis by Controlling the Concentration of Free t-PA , 1991, Thrombosis and Haemostasis.
[12] A. Hamsten,et al. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. , 1990, Arteriosclerosis.
[13] Aric Invest. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators , 1989 .
[14] A. Folsom,et al. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. , 1989, American journal of epidemiology.
[15] E. Kruithof,et al. Diurnal Variation of the Fibrinolytic System , 1988, Thrombosis and Haemostasis.
[16] T. Meade,et al. EFFECTS OF CHANGES IN SMOKING AND OTHER CHARACTERISTICS ON CLOTTING FACTORS AND THE RISK OF ISCHAEMIC HEART DISEASE , 1987, The Lancet.
[17] R. D'Agostino,et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.
[18] M. Blombäck,et al. PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.
[19] P. Vague,et al. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. , 1987, Diabete & metabolisme.
[20] S. Thompson,et al. HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.
[21] R D Moore,et al. Moderate Alcohol Consumption and Coronary Artery Disease: A REVIEW , 1986, Medicine.
[22] G. Wolfbauer,et al. Studies on the binding and degradation of human very-low-density lipoproteins by human hepatoma cell line HepG2. , 1986, Biochimica et biophysica acta.
[23] M. C. Stone,et al. Plasma fibrinogen--a major coronary risk factor. , 1985, The Journal of the Royal College of General Practitioners.
[24] L. Wilhelmsen,et al. Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.
[25] P. Wallén,et al. An Enzyme Linked Immunosorbent Assay for Determination of Tissue Plasminogen Activator Applied to Patients with Thromboembolic Disease , 1983, Thrombosis and Haemostasis.
[26] W. Kannel,et al. Drinking habits and cardiovascular disease: the Framingham Study. , 1983, American heart journal.
[27] H. Ueshima,et al. [The evaluation and the results of cooperative cholesterol and triglyceride standardization program by WHO-CDC (author's transl)]. , 1982, Rinsho byori. The Japanese journal of clinical pathology.
[28] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[29] A. C. Burton,et al. RECOMMENDATIONS for human blood pressure determinations by sphygmomanometers. , 1967, Journal of the American Medical Association.
[30] A. Clauss,et al. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .
[31] G. Assmann,et al. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[32] L. Poller. Recent Advances in Blood Coagulation , 1994 .
[33] L. Mannucci,et al. Hypertriglyceridemia and regulation of fibrinolytic activity. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.
[34] G. Schaafsma,et al. Regular moderate wine consumption for five weeks increases plasma activity of the plasminogen activator inhibitor-1 (PAI-1) in healthy young volunteers , 1990 .
[35] V. Nguyen. Fibrinogen and risk of cardiovascular disease: Kannel WB, Wolf PA, Castelli WP, et al JAMA 258: 1183–1186 Sep 1987 , 1988 .
[36] A. Dyer,et al. Alcohol consumption and 17-year mortality in the Chicago Western Electric Company study. , 1980, Preventive medicine.